[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100556002":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":33,"centralContacts":38,"locations":47,"responsibleParty":99,"collaborators":101,"id":117,"slug":118,"hasResults":119,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":119,"sex":125,"minAge":126,"maxAge":43,"enrollmentInfo":127,"targetDuration":43,"studyType":130,"phases":131,"briefSummary":133,"conditions":134,"keywords":136,"overallStatus":50,"whyStopped":43,"lastUpdateSubmitDate":143,"lastUpdatePostDateStruct":144,"startDateStruct":147,"completionDateStruct":149,"leadSponsor":151,"locationsCount":152},{"fullName":5,"class":6},"London School of Hygiene and Tropical Medicine","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Tranexamic acid (TXA)","EXPERIMENTAL","Tranexamic acid (TXA) 2 x 500 mg oral tablets, taken three times daily from the first to the last day of the menstrual period (maximum 5 days), for six consecutive menstrual cycles (up to a maximum of 9 months). Participants also receive standard of care oral iron and folic acid supplementation for three months from randomisation.",[13],"Drug: Tranexamic Acid 500 MG",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Matching placebo 2 x 500 mg oral tablets, taken three times daily from the first to the last day of the menstrual period (maximum 5 days), for six consecutive menstrual cycles (up to a maximum of 9 months). Participants also receive standard of care oral iron and folic acid supplementation for three months from randomisation.",[19],"Drug: Placebo",[21,29],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Tranexamic Acid 500 MG","Tablets",[9],[27,28],"TXA","Tranexamic Acid",{"type":22,"name":15,"description":24,"armGroupLabels":30,"otherNames":31},[15],[32],"Matched Placebo",[34],{"name":35,"affiliation":36,"role":37},"Professor Ian Roberts","London School of Hygiene and Tropical Medicine (Clinical Trials Unit)","PRINCIPAL_INVESTIGATOR",[39,45],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Eni Balogun","CONTACT","020 7958 8117",null,"woman3@lshtm.ac.uk",{"name":35,"role":41,"phone":46,"phoneExt":43,"email":44},"020 7958 8128",[48,67,84],{"facility":49,"status":50,"city":51,"state":52,"zip":43,"country":53,"countryCode":54,"cosmosGeoPoint":55,"geoPoint":60,"contacts":61},"University College Hospital","RECRUITING","Ibadan","Oyo State","Nigeria","NG",{"type":56,"coordinates":57},"Point",[58,59],3.90591,7.37756,{"lat":59,"lon":58},[62,66],{"name":63,"role":41,"phone":64,"phoneExt":43,"email":65},"Folasade A Bello","+2347067427993","nigeria.woman3@lshtm-ctu.org",{"name":63,"role":37,"phone":43,"phoneExt":43,"email":43},{"facility":68,"status":69,"city":70,"state":43,"zip":43,"country":71,"countryCode":72,"cosmosGeoPoint":73,"geoPoint":77,"contacts":78},"Shifa Tameer e Millat University","NOT_YET_RECRUITING","Islamabad","Pakistan","PK",{"type":56,"coordinates":74},[75,76],73.04329,33.72148,{"lat":76,"lon":75},[79,83],{"name":80,"role":41,"phone":81,"phoneExt":43,"email":82},"Rizwana Chaudhri","+923205514960","pakistan.woman3@lshtm-ctu.org",{"name":80,"role":37,"phone":43,"phoneExt":43,"email":43},{"facility":85,"status":69,"city":86,"state":43,"zip":43,"country":87,"countryCode":43,"cosmosGeoPoint":88,"geoPoint":92,"contacts":93},"Mbeya College of Health and Allied Sciences, University of Dar es Salaam","Mbeya","Tanzania",{"type":56,"coordinates":89},[90,91],33.45,-8.9,{"lat":91,"lon":90},[94,98],{"name":95,"role":41,"phone":96,"phoneExt":43,"email":97},"Projestine Muganyizi","+255688267218","tanzania.woman3@lshtm-ctu.org",{"name":95,"role":37,"phone":43,"phoneExt":43,"email":43},{"type":100,"investigatorFullName":43,"investigatorTitle":43,"investigatorAffiliation":43,"oldNameTitle":43,"oldOrganization":43},"SPONSOR",[102,105,107,109,111,113,115],{"name":103,"class":104},"University of Dar es Salaam, Tanzania (Mbeya College of Health and Allied Sciences)","UNKNOWN",{"name":106,"class":104},"Coefficient Giving (Formerly Open Philanthropy)",{"name":108,"class":6},"Versailles Saint-Quentin-en-Yvelines University",{"name":110,"class":6},"Shifa Tameer-e-Millat University",{"name":112,"class":6},"University College Hospital, Ibadan",{"name":114,"class":104},"The Jon Moulton Charity Trust",{"name":116,"class":6},"University of Edinburgh","100556002","phase-3-tranexamic-acid-for-anaemia-trial-100556002",false,"NCT06519422","Tranexamic Acid for Anaemia Trial","The Effects of Tranexamic Acid on Anaemia, Menstrual Health and the Wellbeing of Women: an International Randomised, Placebo-controlled Trial Among Menstruating Women With Anaemia","WOMAN-3","Inclusion Criteria:\n\n* Adult women aged 18 years and older.\n* Currently menstruating, with menstrual periods occurring at least every 38 days and lasting ≥2 days.\n* Anaemia at screening, defined as hemoglobin (Hb) \\\u003C120 g\u002FL by point-of-care finger prick test.\n* Willing and able to provide informed consent.\n* Able to attend in-person follow-up visits during the trial period.\n\nIndividuals with known thalassaemia and sickle cell disease are eligible to participate and take the trial treatment but will not be given standard of care iron supplementation unless it is prescribed by their own treating clinician. They will continue to receive their usual standard care.\n\nExclusion Criteria:\n\n* Planning to get pregnant during the trial period\n* Already taking TXA\n* Known to have possible contraindications to TXA treatment (including allergy to TXA or its excipients, renal impairment, active thromboembolic disease, history of venous or arterial thrombosis, history of convulsion.)","FEMALE","18 Years",{"count":128,"type":129},4000,"ESTIMATED","INTERVENTIONAL",[132],"PHASE3","Anaemia is when the body does not have enough healthy red blood cells to carry oxygen. It is common in women because they lose blood every month during their periods. Anaemia can womwn make feel tired, weak, dizzy and out of breath. It can also make it harder to study, work or look after their family. If woman become pregnant with anaemia, it can cause problems for both mother and baby, such as early birth or heavy bleeding when giving birth. It is best to treat anaemia in young women well before they get pregnant. Doctors treat anaemia with iron and vitamins. But some people get side effects when taking iron tablets and so they stop taking them. Tranexamic acid (TXA) is a medicine used to treat heavy periods. The investigators of this study would like to find out if taking TXA with the usual iron and vitamin supplements is better at treating anaemia than taking iron and vitamin supplements alone. (Lay Summary)",[135],"Anaemia",[137,138,135,139,140,141,142],"Tranexamic acid","Antifibrinolytic","Menstrual health","Menstruation","Bleeding","Iron Deficiency","2026-08-13",{"date":145,"type":146},"2026-08-17","ACTUAL",{"date":148,"type":146},"2026-08-10",{"date":150,"type":129},"2028-09",{"name":5,"class":6},3]